Scarica l'app Stockscreener
8.24
0.12%
-0.010
Dopo l'orario di chiusura:
8.08
-0.16
-1.94%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GRFS Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Grifols Sa Adr Borsa (GRFS) Ultime notizie
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates - GlobeNewswire Inc.
Grifols S.A. Stock: Navigating Debt Reduction Through US Biopharma IPO Plans Amid Market Pressures - AD HOC NEWS
Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in - AD HOC NEWS
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026 - FinancialContent
Grifols SA stock surges as board greenlights potential US IPO of plasma unit to slash debt and fuel - AD HOC NEWS
Grifols S.A. stock surges on board approval for potential US IPO of biopharma unit - AD HOC NEWS
Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS) - Seeking Alpha
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag By Investing.com - Investing.com India
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag - Investing.com
Earnings call transcript: Grifols Q4 2025 sees robust growth in IG franchise - Investing.com Canada
Grifols falls 6% after skipping 2026 revenue target; €7.52 bln sales - Investing.com
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
Contrasting Grifols (NASDAQ:GRFS) & Sigyn Therapeutics (OTCMKTS:SIGY) - Defense World
Airbus SE – Unsponsored ADR (OTCMKTS:EADSY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Grifols S.A. the Most Slept-On Biotech Play Right Now? - AD HOC NEWS
Revenue per share of Grifols, S.A. Sponsored ADR Class A – MUN:G0F - TradingView — Track All Markets
Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS) - Seeking Alpha
European Index Open Up Ahead of Crucial Data Prints -- Market Talk - 富途牛牛
Price to book ratio of Grifols, S.A. Sponsored ADR Class B – BOATS:GRFS - TradingView
Validea's Top Health Care Stocks Based On Martin Zweig11/12/2025 - Nasdaq
Grifols ADR earnings matched, revenue fell short of estimates By Investing.com - Investing.com UK
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols, S.A.American Depositary Shares (Nasdaq:GRFS) Stock Quote - FinancialContent
Validea Joseph Piotroski Strategy Daily Upgrade Report10/10/2025 - Nasdaq
Arm Holdings PLC ADRhedged (BATS:ARMH) Short Interest Down 33.3% in September - Defense World
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
GRDLY Stock Price, Quote and News - Markets.com
Grifols Announces Interim Dividend for 2025 - The Globe and Mail
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - Benzinga
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - The Globe and Mail
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
6 undervalued stocks with low beta - Morningstar
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Spanish court opens investigation into Gotham City's attack on Grifols - Reuters
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Europe Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper - Reuters
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire
Grifols stock falls amid potential Moody's downgrade, new short report - Seeking Alpha
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF - Macau Business
San Gabriel Valley Tribune - FinancialContent
Cramer 'Takes A Pass' On Stock That's Down 31% Over Past 6 Months: 'Don't Want To Go Against Musk' - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Grifols S.A. Investigated by Block & Leviton For Potential - GlobeNewswire
Which Trades Are Top Funds Making? - Morningstar Canada
Shares at Spain's Grifols rise on cost-cutting plan - Reuters
Grifols SA (GRFS) Stock Price, News & Analyst Forecast - eToro
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - Newswire Canada
0.81%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):